N. Peter

发表

Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B‐cell lymphoma: mature results of a phase II multicentre study

N. Schmitz, M. Gramatzki, H. Wolf, 2015, British journal of haematology.

Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone

M. Ziepert, M. Pfreundschuh, M. Hensel, 2008, Annals of Hematology.

Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma

V. Diehl, J. Glossmann, L. Nogova, 2005, Annals of Hematology.

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.

A. Rosenwald, M. Ziepert, N. Schmitz, 2010, Blood.

Single versus tandem high‐dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long‐term results from the phase III GMMG‐HD2 trial

H. Goldschmidt, Y. Ko, A. Ho, 2016, British journal of haematology.

Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).

D. Niederwieser, G. Ehninger, W. Aulitzky, 2015, Annals of Oncology.

Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphona Study Group (DSHNHL).

M. Ziepert, N. Schmitz, M. Pfreundschuh, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

D. Niederwieser, C. Junghanss, H. Al-Ali, 2009, Leukemia.

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

M. Kersten, H. Goldschmidt, P. Sonneveld, 2014, Haematologica.

Mito-FLAG with Ara-C as Bolus Vs. Continuous Infusion in Recurrent AML – Results of a Prospective Randomized Intergroup Study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemias (SAL)

D. Niederwieser, G. Ehninger, W. Aulitzky, 2008 .

Pegylated asparaginase in combination with high‐dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study

O. Rosen, T. Ittel, J. Boos, 2003, British journal of haematology.

Improvement of overall survival in advanced stage mantle cell lymphoma.

E. Hoster, M. Engelhard, G. Brittinger, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

German High-Grade Non-Hodgkin Lymphoma Study Group analysis of patients with T-cell lymphoma treated in studies of the Treatment and prognosis of mature T-cell and NK-cell lymphoma: an

Markus Loeffler, Anthony D. Ho, Norbert Schmitz, 2013 .

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

Markus Loeffler, Anthony Ho, Norbert Schmitz, 2008, The Lancet. Oncology.

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

W. Klapper, E. Hoster, G. Salles, 2016, The Lancet.

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).

A. Rosenwald, M. Ziepert, N. Schmitz, 2012, The Lancet. Oncology.

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.

D. Hose, H. Goldschmidt, A. Jauch, 2012, Blood.

Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials

D. Niederwieser, S. Scholl, C. Junghanss, 2021, Annals of Hematology.

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.

Martin Dreyling, Michael Unterhalt, Wolfgang Hiddemann, 2006, Blood.

Network German Low Grade Lymphoma Study Group ( GLSG ) and the European Mantle Cell Lymphoma

W. Klapper, E. Hoster, W. Hiddemann, 2007 .

Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO)

D. Niederwieser, S. Scholl, C. Junghanss, 2015, Journal of Cancer Research and Clinical Oncology.

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.

Carsten Müller, M. Pfreundschuh, M. Wiesen, 2012, Blood.

Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study

W. Hiddemann, B. Dörken, A. Krämer, 2023, Annals of Hematology.

Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study

W. Hiddemann, A. Krämer, D. Niederwieser, 2016 .

Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia.

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Response Adapted Assignment of the Number of Chemotherapy Cycles for the Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Is Not Justified: Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

M. Ziepert, N. Schmitz, M. Pfreundschuh, 2007 .

The Addition of Rituximab to CHOP Improves Failure-Free and Overall Survival of Mantle-Cell Lymphoma Patients – a Pooled Trials Analysis of the German Low-Grade Lymphoma Study Group (GLSG)

W. Klapper, E. Hoster, W. Hiddemann, 2014 .

Circulating Tumor Cells As a Surrogate Marker for Bone Marrow Minimal Residual Disease and an Adverse Prognostic Factor for Patients with Multiple Myelom

H. Goldschmidt, T. Hielscher, M. Vogel, 2017 .

deletion 17p transplantation improves outcome in multiple myeloma patients with Administration of bortezomib before and after autologous stem cell

D. Hose, H. Goldschmidt, A. Jauch, 2012 .

Dose-Dense Rituximab in Combination with Biweekly CHOP-14 for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Phase-I/II and Pharmacokinetic Study of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

N. Schmitz, M. Pfreundschuh, S. Wessendorf, 2006 .

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.

A. Rosenwald, M. Ziepert, N. Schmitz, 2010, Blood.